Search research articles
Contact Us
Filters
Showing results (61-70 of 89) with videos related to
Page
of 9
Sort By:
Advances in Preventive Medicine
|
October 13, 2011
Immunogenicity of Simulated PCECV Postexposure Booster Doses 1, 3, and 5 Years after 2-Dose and 3-Dose Primary Rabies Vaccination in Schoolchildren
Thavatchai Kamoltham, Wiravan Thinyounyong, Pakamatz Khawplod, et al.
The Pediatric Infectious Disease Journal
|
April 1, 2009
A three-year clinical study on immunogenicity, safety, and booster response of purified chick embryo cell rabies vaccine administered intramuscularly or intradermally to 12- to 18-month-old Thai children, concomitantly with Japanese encephalitis vaccine
Krisana Pengsaa, Kriengsak Limkittikul, Arunee Sabchareon, et al.
Human Vaccines & Immunotherapeutics
|
April 14, 2017
Comparison of the immunogenicity and safety of the purified chick embryo cell rabies vaccine manufactured in India and Germany: A randomized, single blind, multicentre, phase IV clinical study
Gadey Sampath, Angelika Banzhoff, Alaka Deshpande, et al.
Pharmatherapeutica
|
January 1, 1985
Renal tolerance of ofloxacin, a new gyrase inhibitor
M Verho, E E Dagrosa, P Usinger, et al.
Arzneimittel-Forschung
|
August 1, 1993
Dose relationship of stimulated insulin production following intravenous application of glimepiride in healthy man
K Ratheiser, A Korn, W Waldhäusl, et al.
The Journal of Pediatrics
|
July 24, 2007
Pre-exposure rabies vaccination using purified chick embryo cell rabies vaccine intradermally is immunogenic and safe
Thavatchai Kamoltham, Wirawan Thinyounyong, Phana Phongchamnaphai, et al.
Chemotherapy
|
January 1, 1988
Safety, tolerance and pharmacokinetics of 2.0 g cefpirome (HR 810) after single and multiple dosing
M Badian, V Malerczyk, J D Collins, et al.
Vaccine
|
November 8, 2022
Can risk area designation help increase vaccination coverage for Tick-Borne Encephalitis? Evidence from German claims data
M Ghiani, C Hagemann, J Friedrich, et al.
Scandinavian Journal of Gastroenterology
|
June 1, 1987
The effects of 75 mg HOE 760, a novel H2-receptor antagonist, on daytime peptone-stimulated and nocturnal gastric acid output in healthy volunteers
F Hagenmüller, C Weber, S Hausmann, et al.
Gene Therapy
|
October 22, 2004
Ribozyme targeting of the growth factor pleiotrophin in established tumors: a gene therapy approach
C Malerczyk, A M Schulte, F Czubayko, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 89) with videos related to
Sort By:
Page
of 9
Advances in Preventive Medicine
|
October 13, 2011
Immunogenicity of Simulated PCECV Postexposure Booster Doses 1, 3, and 5 Years after 2-Dose and 3-Dose Primary Rabies Vaccination in Schoolchildren
Thavatchai Kamoltham, Wiravan Thinyounyong, Pakamatz Khawplod, et al.
The Pediatric Infectious Disease Journal
|
April 1, 2009
A three-year clinical study on immunogenicity, safety, and booster response of purified chick embryo cell rabies vaccine administered intramuscularly or intradermally to 12- to 18-month-old Thai children, concomitantly with Japanese encephalitis vaccine
Krisana Pengsaa, Kriengsak Limkittikul, Arunee Sabchareon, et al.
Human Vaccines & Immunotherapeutics
|
April 14, 2017
Comparison of the immunogenicity and safety of the purified chick embryo cell rabies vaccine manufactured in India and Germany: A randomized, single blind, multicentre, phase IV clinical study
Gadey Sampath, Angelika Banzhoff, Alaka Deshpande, et al.
Pharmatherapeutica
|
January 1, 1985
Renal tolerance of ofloxacin, a new gyrase inhibitor
M Verho, E E Dagrosa, P Usinger, et al.
Arzneimittel-Forschung
|
August 1, 1993
Dose relationship of stimulated insulin production following intravenous application of glimepiride in healthy man
K Ratheiser, A Korn, W Waldhäusl, et al.
The Journal of Pediatrics
|
July 24, 2007
Pre-exposure rabies vaccination using purified chick embryo cell rabies vaccine intradermally is immunogenic and safe
Thavatchai Kamoltham, Wirawan Thinyounyong, Phana Phongchamnaphai, et al.
Chemotherapy
|
January 1, 1988
Safety, tolerance and pharmacokinetics of 2.0 g cefpirome (HR 810) after single and multiple dosing
M Badian, V Malerczyk, J D Collins, et al.
Vaccine
|
November 8, 2022
Can risk area designation help increase vaccination coverage for Tick-Borne Encephalitis? Evidence from German claims data
M Ghiani, C Hagemann, J Friedrich, et al.
Scandinavian Journal of Gastroenterology
|
June 1, 1987
The effects of 75 mg HOE 760, a novel H2-receptor antagonist, on daytime peptone-stimulated and nocturnal gastric acid output in healthy volunteers
F Hagenmüller, C Weber, S Hausmann, et al.
Gene Therapy
|
October 22, 2004
Ribozyme targeting of the growth factor pleiotrophin in established tumors: a gene therapy approach
C Malerczyk, A M Schulte, F Czubayko, et al.
Page
of 9